Hospital Universitario 12 Of Octobre

Villanueva de Córdoba, Spain

Hospital Universitario 12 Of Octobre

Villanueva de Córdoba, Spain
SEARCH FILTERS
Time filter
Source Type

Archer T.,Gothenburg University | Kostrzewa R.M.,East Tennessee State University | Palomo T.,Hospital Universitario 12 Of Octobre | Beninger R.J.,Queen's University
Neurotoxicity Research | Year: 2010

The prevailing utility, and indeed necessity, of clinical staging models applied in considerations of neuropsychiatric disease progressions is discussed from the perspectives of schizophrenia spectrum disorders and affective disorders, cannabis in schizopsychotic disorder, incidences of affect and psychosis, staging disorders in aging and the indices and prevalence of apathy. There would appear to be a strong current consensus that the pursuit of clinical staging of these and other brain disease states has contributed a systematic conceptual instrument to facilitate the better understanding, diagnosis, prognosis and treatment as derived from a multitude of genetic predispositions, symptoms and syndromes, early-onset and prodromal phases, recurrences and relapses, that have complicated the situation of the patient. Through a staging determination of the disorder, elements of diagnosis will describe the progression of symptoms/syndromes through pre-onset, prodromal, first-episode, recurrences and relapses, and treatment resistance thereby facilitating the eventual prognosis, intervention alternatives and treatment. This approach varies from observations of individuals at early stages of development (infancy, childhood, adolescece) to early middle age, in the case of diseases expressed through the aging processes. Essentially, the major contribution of the staging model may lie in the early identification, diagnosis, and treatments of disorders that afflict the brain and central nervous system. © 2010 Springer Science+Business Media, LLC.


Archer T.,Gothenburg University | Kostrzewa R.M.,East Tennessee State University | Beninger R.J.,Queen's University | Palomo T.,Hospital Universitario 12 Of Octobre
Neurotoxicity Research | Year: 2010

Neurodevelopmental risk factors have assumed a critical role in prevailing notions concerning the etiopathogenesis of neuropsychiatric disorders. Staging, diagnostic elements at which phase of disease is determined, provides a means of conceptualizing the degree and extent of factors affecting brain development trajectories, but is concurrently specified through the particular interactions of genes and environment unique to each individual case. For present purposes, staging perspectives in neurodevelopmental aspects of the disease processes are considered from conditions giving rise to neurodevelopmental staging in affective states, adolescence, dopamine disease states, and autism spectrum disorders. Three major aspects influencing the eventual course of individual developmental trajectories appear to possess an essential determinant influence upon outcome: (i) the type of agent that interferes with brain development, whether chemical, immune system activating or absent (anoxia/hypoxia), (ii) the phase of brain development at which the agent exerts disruption, whether prenatal, postnatal, or adolescent, and (iii) the age of expression of structural and functional abnormalities. Clinical staging may be assumed at any or each developmental phase. The present perspective offers both a challenge to bring further order to diagnosis, intervention, and prognosis and a statement regarding the extreme complexities and interwoven intricacies of epigenetic factors, biomarkers, and neurobehavioral entities that aggravate currents notions of the neuropsychiatric disorders. © 2010 Springer Science+Business Media, LLC.


Martin Hernandez E.,Hospital Universitario 12 Of Octobre | Garcia Silva M.T.,Hospital Universitario 12 Of Octobre | Quijada Fraile P.,Hospital Universitario 12 Of Octobre | Martinez De Aragon A.,Hospital Universitario 12 Of Octubre | And 2 more authors.
Acta Pediatrica Espanola | Year: 2010

Kearns-Sayre (KSS) and Pearson syndromes are both multisystem mitochondrial diseases whose underlying genetic defect is a single large-scale mitochondrial DNA (mtDNA) deletion. Objectives: To describe the clinical spectrum of KSS and PS, with the object of spreading the knowledge of these disease to the pediatricians. Patients and methods: We reviewed the clinical notes of 6 patients diagnosed with KSS and 3 patients initially diagnosed with PS. Results: The age at the onset was lower in PS patients. First appearing symptoms were hematological (anemia), followed by renal (Fanconi) and digestive involvement (pancreatic insufficiency). Ophthalmological, endocrinological, cardiological and neurological symptoms were manifested at later stages. Four patients required pacemaker implantation. Six showed cerebral and/or brain stem involvement in MRI. CSF analysis showed increased levels of both lactic acid and proteins whereas folate levels were diminished. Half of the KSS patients showed ragged-red fibers and COX negative fibers in their skeletal muscle. A large-scale mtDNA deletion was found in eight patients. Conclusions: 1. The most remarkable differences between PS and KSS were the age at presentation and the initial clinical symptoms; symptoms during evolution, and biochemical, neuroradiological and genetic findings were similar in both disorders, 2. Mitochondrial diseases should be included in the differential diagnosis of the Fanconi syndrome, growth hormone deficiency and cardiac conduction disorders. A single large-scale mtDNA is essential to confirm the diagnosis.


Santos-Lozano A.,University of León | Santos-Lozano A.,Hospital Universitario 12 Of Octobre | Sanchis-Gomar F.,Hospital Universitario 12 Of Octobre | Pareja-Galeano H.,European University at Madrid | And 7 more authors.
Rejuvenation Research | Year: 2015

The world population is continuously aging, and centenarians may be considered to be the most successfully aged individuals. Among people who reach extreme longevity (EL; i.e., > 95 years), supercentenarians (SCs; aged ≥ 110 years) represent a subgroup of great scientific interest. Unfortunately, data on the worldwide distribution of SCs remain scarce. Therefore, this study was designed to investigate this issue. Current available data indicate that Japan is the country with the highest number of currently alive SCs. Interestingly, Puerto Rico would show the highest prevalence of SCs among people who reach EL (approximately one SC per 10,000 inhabitants aged ≥ 95 years), although data on this country must be intrepreted with caution owing to potential methodological limitations, mainly related to its small population. Our findings highlight the need to investigate in greater detail the genetic and lifestyle background of SCs, with the ultimate goal of unraveling new potential mechanisms underlying human EL. © Mary Ann Liebert, Inc.

Loading Hospital Universitario 12 Of Octobre collaborators
Loading Hospital Universitario 12 Of Octobre collaborators